{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360298345304985088.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1093/cid/ciy760"}},{"identifier":{"@type":"URI","@value":"http://academic.oup.com/cid/article-pdf/68/10/1641/28543444/ciy760.pdf"}}],"dc:title":[{"@value":"Oral Versus Aerosolized Ribavirin for the Treatment of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant Recipients"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380298345304985089","@type":"Researcher","foaf:name":[{"@value":"Farnaz Foolad"}],"jpcoar:affiliationName":[{"@value":"Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298345304985092","@type":"Researcher","foaf:name":[{"@value":"Samuel L Aitken"}],"jpcoar:affiliationName":[{"@value":"Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston"},{"@value":"Center for Antimicrobial Resistance and Microbial Genomics, UTHealth McGovern Medical School, Houston"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298345304985094","@type":"Researcher","foaf:name":[{"@value":"Terri Lynn Shigle"}],"jpcoar:affiliationName":[{"@value":"Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298345304985093","@type":"Researcher","foaf:name":[{"@value":"Amrita Prayag"}],"jpcoar:affiliationName":[{"@value":"Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298345304985088","@type":"Researcher","foaf:name":[{"@value":"Shashank Ghantoji"}],"jpcoar:affiliationName":[{"@value":"Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298345304985090","@type":"Researcher","foaf:name":[{"@value":"Ella Ariza-Heredia"}],"jpcoar:affiliationName":[{"@value":"Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298345304985091","@type":"Researcher","foaf:name":[{"@value":"Roy F Chemaly"}],"jpcoar:affiliationName":[{"@value":"Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"10584838"},{"@type":"EISSN","@value":"15376591"}],"prism:publicationName":[{"@value":"Clinical Infectious Diseases"}],"dc:publisher":[{"@value":"Oxford University Press (OUP)"}],"prism:publicationDate":"2018-09-08","prism:volume":"68","prism:number":"10","prism:startingPage":"1641","prism:endingPage":"1649"},"reviewed":"false","dc:rights":["https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model"],"url":[{"@id":"http://academic.oup.com/cid/article-pdf/68/10/1641/28543444/ciy760.pdf"}],"createdAt":"2018-08-30","modifiedAt":"2019-05-02","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/2050025942155225216","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Molecular mechanisms of the medicines for COVID-19"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1093/cid/ciy760"},{"@type":"CROSSREF","@value":"10.1246/bcsj.20220179_references_DOI_WsvsscTAraK12op32gzTihavlmm"}]}